Manoj (for Akash)'s questions to Arvinas Inc (ARVN) leadership • Q3 2024
Question
An analyst, Manoj, asked if the base case assumption should be that Arvinas and Pfizer will advance the vepdegestrant combination with Pfizer's CDK4 inhibitor, atirmociclib, in both first-line and second-line settings.
Answer
John Houston, CEO, President, and Chairperson, responded that while the company would be very excited if the data supports the atirmociclib combination, the decision will be data-driven. He noted that data from the ongoing palbociclib combination trial will also be available this year to inform the final strategy with Pfizer.